Acromegaly: Underdiagnosed in patients with prolactinoma

Ekaterina Manuylova, G. Edward Vates, Ismat Shafiq

Department of Endocrinology, Diabetes and Metabolism, University of Rochester, 601 Elmwood Ave, Rochester, NY, USA. Department of Neurosurgery, University of Rochester, 2180 South Clinton Ave, Rochester, NY, USA


Prolactin secreting adenomas are very common and account for 50-60% of all functional pituitary adenomas.  Medical history pertaining to reproductive and sexual function initiates the work up for prolactinoma. At the time of initial assessment other pituitary hormones may be evaluated, including growth hormone (GH). Thereafter, patients are treated medically with dopamine agonist, typically with no further assessment of GH hypersecretion. Review of the literature suggests that up to 4% of patients with an established diagnosis of prolactinoma can develop acromegaly even after many years of the initial evaluation. Acromegaly is a rare disease with mortality rates 2-3 times higher as compared to that of the general population. The interval from onset of symptoms to the diagnosis may range from one year to several decades. Thus, omitting IGF-1 measurements at the initial evaluation of prolactinoma, and/or in the follow up period, can miss mild and subtle cases of acromegaly. Therefore, biochemical evaluation for GH excess should be considered in patients with prolactinoma initially as well as in the remote follow up. Journal of Nature and Science (JNSCI), 3(8):e418, 2017



HomeAbout JNSCI Privacy PolicyPeer ReviewPub Fee
Author Guidance 

©2017 Journal of Nature and Science (JNSCI), Los Angeles, CA, USA | ISSN 2377-2700 | Contact: editor@jnsci.org